Department of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy.
Department of Infectious Diseases, Istituto Superiore di Sanità, Viale Regina Elena Rome 299, 00161, Rome, Italy.
Infection. 2018 Dec;46(6):867-870. doi: 10.1007/s15010-018-1174-9. Epub 2018 Jul 6.
Dihydroartemisinin-piperaquine (DHA-PPQ) is the artemisinin combination therapy that was recently introduced for the treatment of Plasmodium falciparum uncomplicated malaria, but emerging resistance in South-East Asia is threatening its use. This report describes a case of DHA-PPQ treatment failure in uncomplicated malaria occurring in an immigrant living in Italy, after a travel to Ethiopia. Thirty days after malaria recovery following DHA-PPQ therapy, the patient had malaria recrudescence. According to the genotyping analysis, the same P. falciparum was responsible for both episodes. Thus, it seems important to consider possible malaria recrudescence occurring after DHA-PPQ therapy in patients from African countries.
双氢青蒿素-哌喹（DHA-PPQ）是一种青蒿素类复方疗法，最近被引入用于治疗无并发症的恶性疟原虫疟疾，但在东南亚出现的抗药性正在威胁其使用。本报告描述了一例在意大利生活的移民在前往埃塞俄比亚旅行后，出现无并发症疟疾且 DHA-PPQ 治疗失败的病例。在 DHA-PPQ 治疗后 30 天，患者疟疾复发。根据基因分型分析，两次感染均由同一株恶性疟原虫引起。因此，对于来自非洲国家的患者，在 DHA-PPQ 治疗后，可能会出现疟疾复发，这一点似乎很重要。
